Finding. TMEM70 is how most nuclear ATP-synthase (Complex V) deficiency is born, and the heart is the organ that fails first. Palacios-Contreras, Cyganek, Pavez-Giani and colleagues build the missing human model: CRISPR the gene in induced pluripotent stem cells, then make cardiomyocytes. In the stem-cell state, mitochondria still work. After differentiation, membrane potential falls, respiratory capacity falls, and the cells remodel as if they were already in a cardiomyopathy. That is a maturation gate, not a generic 'mito is down' stain.
Chronic AMP-activated protein kinase (AMPK) activation puts respiratory capacity back even though Complex V stays broken. Proteomics and metabolomics say the same sentence in two dialects: mitochondrial and fatty-acid metabolism are reinforced, pathological structural remodeling is suppressed, and cardiac function improves. AMPK is not assembling missing synthase. It is changing the neighborhood the broken synthase lives in.
Why this paper matters TMEM70 disease has been a genetics and biochemistry story (assembly factor, ATP synthase, neonatal lactic acidosis, hypertrophic cardiomyopathy) without a clean human muscle cell. Mouse and patient fibroblasts do not have to become working cardiomyocytes. Here the lesion is quiet until the cell takes on a heart identity. That is useful twice. First, it tells you where to look: metabolic maturation, not pluripotent OCR. Second, it gives AMPK a specific job in mitochondrial cardiomyopathy, as a state-dependent workaround rather than a Complex V patch.
The field already loves AMPK in ischemia and in metformin folklore. This preprint is sharper. The synthase is still deficient. Respiration returns anyway. If that holds in the figures, AMPK agonists become a hypothesis for nuclear ATP-synthase heart disease, not a claim that you fixed the enzyme.
How to read the score Low nineties. Primary mitochondrial disease, the common nuclear Complex V gene, a human cardiomyocyte, a differentiation-gated failure, and a metabolic rescue with proteome and metabolome attached. Confidence is medium because the abstract does not name the AMPK ligand, the dose, or the cardiac-function assay. Heuristic copy would have said 'AMPK helps sick mitochondria.' The paper says AMPK rewires a Complex V-deficient cardiomyocyte after a maturation collapse.
Caveats A dish of stem-cell cardiomyocytes is not a neonate. 'Improved cardiac function' could be engineered-tissue twitch, calcium, or something else; the abstract will not tell you. Persistent Complex V deficiency means any rescue is compensatory. Nobody should change a TMEM70 patient's care from this brief.
What to do with it If you track mitochondrial cardiomyopathy or ATP-synthase assembly, this is the week's human-cell paper. If you build AMPK or fatty-acid programs, steal the design: lesion silent in iPSCs, loud in cardiomyocytes, rescue scored on respiration plus remodeling, not on synthase activity. Pull the proteomic and metabolomic tables before you write that AMPK cured Complex V disease.